Hakura Atsushi, Suzuki Satoshi, Sawada Shigeki, Sugihara Tadakazu, Hori Yuji, Uchida Kanako, Kerns William D, Sagami Fumio, Motooka Satoru, Satoh Tetsuo
Department of Developmental Safety Assessment Research, Eisai Co, Ltd, 1, Takehaya-machi, Kawashima-cho, Hashima-gun, Gifu 501-6195, Japan.
Regul Toxicol Pharmacol. 2003 Feb;37(1):20-7. doi: 10.1016/s0273-2300(02)00024-7.
The purpose of the present study was to examine the inter-individual variation in the mutagenicity of chemicals using a variety of human S9 fractions. For this purpose, three procarcinogens, 2-amino-3-methylimidazo[4,5-f]quinoline (IQ), benzo[a]pyrene (BP), and dimethylnitrosamine (DMN), were selected for the Ames test and their mutagenicity was examined using human liver S9 fractions prepared from 18 different donors and one pooled liver S9 fraction prepared from 15 different donors. In addition, rat S9 fraction prepared from male rats pretreated with phenobarbital and 5,6-benzoflavone (PB/BF) was used as reference in order to examine the mutagenic differences between human and rat (PB/BF) S9 fractions. The data demonstrate a large inter-individual diversity in the mutagenic response to procarcinogens. The mutagenicity of IQ and BP in the presence of a human liver S9 fraction (lot HLS-014) was equal to that observed in the presence of rat (PB/BF) S9 fraction. The mutagenicity of IQ and BP in the presence of a pooled human liver S9 fraction was lower (90 and 95%, respectively) than that observed in the presence of rat (PB/BF) S9. On the contrary, the mutagenicity of DMN in the presence of either a selected human liver S9 fraction (lot HLS-014) or pooled fraction was 8-fold higher than that found in the presence of rat (PB/BF) S9 fraction. Human liver S9 fraction (lot HLS-014) had one of the highest cytochrome P450 enzyme activities among the 18 different donors and higher than the pooled human liver S9 fraction. These results suggest that the use of both selected human liver S9 fractions with high metabolic activity (e.g., lot HLS-014 as used in this study) and a pooled S9 fraction with moderate metabolic activity could be used as a means to evaluate the inter-individual variability in mutagenic response to chemicals and to confirm positive responses from studies completed with rodent S9.
本研究的目的是使用多种人源S9组分来检测化学物质致突变性的个体间差异。为此,选择了三种前致癌物2-氨基-3-甲基咪唑[4,5-f]喹啉(IQ)、苯并[a]芘(BP)和二甲基亚硝胺(DMN)进行艾姆斯试验,并使用从18个不同供体制备的人肝S9组分以及从15个不同供体制备的一个混合肝S9组分检测它们的致突变性。此外,使用从经苯巴比妥和5,6-苯并黄酮(PB/BF)预处理的雄性大鼠制备的大鼠S9组分作为对照,以检测人源和大鼠(PB/BF)S9组分之间的致突变差异。数据表明,对前致癌物的致突变反应存在很大的个体间差异。在人肝S9组分(批次HLS-014)存在下,IQ和BP的致突变性与在大鼠(PB/BF)S9组分存在下观察到的致突变性相当。在混合人肝S9组分存在下,IQ和BP的致突变性低于在大鼠(PB/BF)S9存在下观察到的致突变性(分别为90%和95%)。相反,在所选人肝S9组分(批次HLS-014)或混合组分存在下,DMN的致突变性比在大鼠(PB/BF)S9组分存在下高8倍。人肝S9组分(批次HLS-014)在18个不同供体中具有最高的细胞色素P450酶活性之一,且高于混合人肝S9组分。这些结果表明,使用具有高代谢活性的所选人肝S9组分(如本研究中使用的批次HLS-014)和具有中等代谢活性的混合S9组分,可作为评估化学物质致突变反应个体间变异性以及确认用啮齿动物S9完成的研究中的阳性反应的一种方法。